SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma EP News Bureau Dec 8, 2021 SPARC to receive equity in Visiox along with other financial considerations
SPARC announces Phase 3 trial results of SDN-037 to treat inflammation and pain of ocular surgery EP News Bureau Oct 14, 2020 The primary efficacy measure was the proportion of subjects with an anterior chamber cell (ACC) grade of zero (0) on Day 15 (zero…
